Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30890284 | 1.00 | LMNA (0.65) | LMNAALDH1A1MAPTSLC6A9SLC6A5 | |
| SCHEMBL13419584 | 0.96 | ALDH1A1 (0.60) | LMNAALDH1A1MAPTSLC6A9SLC6A5 | |
| SCHEMBL448246 | 0.91 | ALDH1A1 (0.68) | LMNAALDH1A1MAPTSLC6A9SMN1; SMN2 | |
| SCHEMBL23783085 | 0.91 | ALDH1A1 (0.54) | LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL31700489 | 0.88 | ALDH1A1 (0.52) | LMNAALDH1A1MAPTSLC6A9MET | |
| SCHEMBL29213999 | 0.87 | ALDH1A1 (0.49) | LMNAALDH1A1MAPTSLC6A9SLC6A5 | |
| SCHEMBL30207461 | 0.87 | ALDH1A1 (0.50) | LMNAALDH1A1MAPTSLC6A9SLC6A5 | |
| SCHEMBL23783375 | 0.87 | ALDH1A1 (0.50) | LMNAALDH1A1MAPTSLC6A9SLC6A5 | |
| SCHEMBL994347 | 0.86 | ALDH1A1 (0.68) | LMNAALDH1A1MAPTSLC6A9SLC6A5 | |
| SCHEMBL29536266 | 0.86 | ALDH1A1 (0.68) | LMNAALDH1A1MAPTSLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-03-27 | — | — | US | disclosed |
| US-20240308996-A1 | PYRIDOPYRIDINES AND DERIVATIVES THEREOF AS SELECTIVE KINASE INHIBITORS | UNIVERSITY OF SHARJAH (AE) | 2024-09-19 | — | — | US | disclosed |
| EP-4384521-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-117794936-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023018237-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| CN-112601752-A | Novel inhibitors of MAP4K1 | 伊克诺斯科学公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3630778-A1 | NOVEL INHIBITORS OF MAP4K1 | Ichnos Sciences SA (CH) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215668-A1 | NOVEL INHIBITORS OF MAP4K1 | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-29 | — | — | WO | disclosed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| EP-0885213-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0885213-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997025323-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | LMNA 2201/4885ALDH1A1 4008/4885MAPT 2055/4885 |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | PDPK1, PI4KA, PIP4K2A | LMNA 4019/4885ALDH1A1 905/4885MAPT 3946/4885 |
| US-20240308996-A1 | PYRIDOPYRIDINES AND DERIVATIVES THEREOF AS SELECTIVE KINASE INHIBITORS | MAP4K2, MAP4K1, MAP3K1 | LMNA 1090/4885ALDH1A1 4055/4885MAPT 998/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | LMNA 4019/4885ALDH1A1 905/4885MAPT 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.